Vascurie

Vascurie is a South Korean biotechnology company focused on developing first-in-class therapeutics for vascular-related disorders. The company's core platform centers on vascular stabilization and the regulation of angiogenesis to treat life-threatening and chronic conditions such as sepsis, age-related macular degeneration (AMD), and diabetic retinopathy. By targeting key molecular drivers of vascular leakage and endothelial dysfunction, Vascurie aims to restore vascular integrity and improve patient outcomes. Its pipeline consists of peptide and protein-based drug candidates currently in the preclinical and early developmental stages. The company was founded on the pioneering research of Professor Young-myeong Kim from Kangwon National University.